Calquence (acalabrutinib)

pCPA File Number: 23425

Negotiation Status:

Active Negotiation

Indication(s):

Indicated in combination with venetoclax for the treatment of patients with previously untreated CLL.

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

PC0412-000

pCPA Engagement Letter Issued:

2026-02-02

Negotiation Process Concluded:

Not Applicable